Artificial intelligence-based drug designer Atomwise has launched two new joint venture projects—one to test its bespoke molecules in living tumor organoids and another to develop targeted inhibitors of a protein linked to triple-negative breast cancer.
For the former, the company’s work with SEngine Precision Medicine aims to create targeted cancer therapies through what they describe as “in vitro clinical trials”—using organoids derived and grown from individual patients’ tumor cells to screen hundreds of potential drugs and combinations.
To start, the Seattle-based SEngine will provide gene targets related to cancer growth; then, Atomwise will use its AI programs to develop personalized small-molecule inhibitors that will be tested within the organoid models.
